Form 4: United Therapeutics Exec Trades Shares

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported a series of transactions involving the exercise of stock options and sale of common stock on April 1, 2026, under a 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, executed a series of transactions on April 1, 2026.
• These transactions involved the exercise of 9,500 stock options at an exercise price of $146.03 per share.
• Following the exercise, 9,500 shares of common stock were sold at a weighted average price of $570.86 to $596.20.
• These trades were conducted under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, which continues until the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, whichever comes first.
• Following these transactions, Rothblatt directly beneficially owns 40,513 shares of common stock.
• Additional shares are held indirectly through trusts and by a spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details routine insider transactions executed under a pre-established plan, rather than signaling new strategic developments or significant shifts in beneficial ownership beyond the plan's scope.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a structured and potentially pre-determined approach to managing equity.
• The exercise of options and subsequent sale of shares at prices significantly higher than the exercise price ($570.86-$596.20 vs $146.03) suggests a profitable transaction for the reporting person.

Negatives

• A significant number of shares (9,500) were sold, which could be interpreted as a reduction in the reporting person's direct stake in the company, although executed under a plan.

Risks

• The 10b5-1 plan has an expiration date of December 31, 2026, or upon exercise of all remaining options, introducing a time-bound element to future transactions.
• The plan is tied to the exercise of stock options that expire on March 17, 2027, creating a potential need for further transactions to manage these options before expiration.

Future Outlook

The 10b5-1 trading plan remains active until December 31, 2026, or until all 1,734,410 stock options are exercised, indicating potential for further transactions within this period.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by a CEO is common practice to diversify holdings or manage personal finances in a pre-determined, non-insider-trading-violating manner, especially in the biopharmaceutical sector where stock-based compensation is prevalent.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a 10b5-1 plan, may be scrutinized by investors. However, the plan's existence suggests a structured approach to avoid perceptions of opportunistic trading.
• Employees: The reporting person's continued direct ownership, albeit reduced, and indirect holdings suggest ongoing commitment.
• Management: The transactions reflect standard executive compensation management practices.

Next Steps

• Continue executing the 10b5-1 trading plan until its termination conditions are met.
• Monitor future Form 4 filings for any additional transactions by Martine A. Rothblatt.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Stock Options, 10b5-1 Plan, Insider Trading, Beneficial Ownership, Martine Rothblatt, Common Stock, Shareholder